News

bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding...

bit.bio, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability R...

bit.bio launches Early Access for ioHepatocytes for disease and drug studies with consistent, functional human iPSC-derived hepato...

Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets.

Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interferenc...

Adding New Visualisation Functionality to Human iPSC-derived Cell Types

Explore insights from bit.bio Senior Scientist Andreas as he shares his experiences judging the iGEM competition.

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the bro...